Title Page
Contents
국문요약 6
서론(Introduction) 25
연구 방법 (Materials and methods) 29
결과 (Results) 35
고찰 (Discussion) 43
결론 (Conclusion) 54
참고문헌(Reference) 55
영문요약 60
Table 1. Baseline patient characteristics according to chemotherapy regimen 9
Table 2. Baseline patient characteristic according to hENT1 expression 11
Table 3. Baseline patient characteristics according to hENT1 expression 13
Table 4. Objective response according to regimen and hENT1 expression 15
Table 5. Univariate and multivariate models of risk factors for progression-free survival 16
Figure 1. Patient flow diagram. We conducted a retrospective review of 153 patients who underwent first-line AG or FOLFIRINOX after excluding 232 patients based on the criteria... 17
Figure 2. These slides depict histological images from mPC patients. The slides were stained with an anti-human equilibrativenucleoside transporter 1 (hENT1) primary rabbit monoclonal... 18
Figure 3. Kaplan-Meier overall survival curves by first-line chemotherapy regimen and hENT1 expression. The median OS was 15.4 months in the AG with strong hENT1 group,... 19
Figure 4. Kaplan-Meier progression-free survival curves by first-line chemotherapy regimen and hENT1 expression. The median PFS was 7.8 months in the AG with strong hENT1 group,... 20
Figure 5. Kaplan-Meier survival curve for patients in the AG with strong hENT1 group compared with those in all other groups. (A) The median OS and 1-year OS rate were 15.4... 21
Figure 6. Kaplan-Meier survival curve in patients treated with a gemcitabine regimen (including AG) as first- or second-line chemotherapy. The median OS and 1-year OS were... 22
Figure 7. Kaplan-Meier survival curve in patients with ECOG 0 or 1 and liver metastasis. (A) The median OS was 15.7 months in the AG with strong hENT1 group (n=26) and 10.8 months... 23
Figure 8. Kaplan-Meier survival curve in patients with ECOG 0 or 1 and without liver metastasis. (A) The median OS was 13.0 months in the AG with strong hENT1 group (n=5)... 24